federal_register: E9-23764

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts regulation_id_numbers
E9-23764 Oncologic Drugs Advisory Committee; Cancellation Notice The meeting of the Oncologic Drugs Advisory Committee scheduled for October 6, 2009, is cancelled. This meeting was announced in the Federal Register of August 25, 2009 (74 FR 42907). The October 6, 2009, Oncologic Drugs Advisory Committee meeting was to discuss ApoPharma, Inc.'s new drug application (NDA) 021-825 for proposed trade name FERRIPROX (deferiprone) film-coated tablets. This meeting has been cancelled to allow time for FDA to review and resolve several outstanding issues. The agency intends to continue evaluating NDA 021- 825 and, as needed, may schedule an advisory committee meeting in the future. 2009-10-02 2009 10 https://www.federalregister.gov/documents/2009/10/02/E9-23764/oncologic-drugs-advisory-committee-cancellation https://www.govinfo.gov/content/pkg/FR-2009-10-02/pdf/E9-23764.pdf Health and Human Services Department; Food and Drug Administration 221,199 The meeting of the Oncologic Drugs Advisory Committee scheduled for October 6, 2009, is cancelled. This meeting was announced in the Federal Register of August 25, 2009 (74 FR 42907). The October 6, 2009, Oncologic Drugs Advisory Committee meeting was...  

Links from other tables